RegulatoryCompany release

FDA grants orphan drug designation to Noema's basimglurant for trigeminal neuralgia

Noema Pharma AG · Mon 16 Nov 2026

Noema Pharma's oral mGluR5 modulator, already on the FDA's Fast Track, now also carries orphan status for the rare and painful neuropathic condition.

The US Food and Drug Administration has granted orphan drug designation to basimglurant, Noema Pharma's investigational treatment for trigeminal neuralgia. The Swiss company announced the decision on 16 November 2026. The compound was formerly known as NOE-101.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release: Noema Pharma AG ↗

Article written by VigiEye from the official source (Noema Pharma AG). Claims are the company's own. AI-assisted; check the source before acting.

More Regulatory All →